The following article is a special editorial authored by Robert K. Stoelting, MD,
On October 13, 2006, the APSF conducted a workshop in response to concerns about the safety of using patient-controlled analgesia (PCA) in the postoperative period.1 The workshop focused on improved detection of postoperative opioid-induced respiratory depression. A number of clinical observations and recommendations resulted including:
We believe that unexpected and potentially harmful opioid-induced respiratory depression continues to occur. In most cases, there is inadequate monitoring (as described above) of oxygenation and/or especially ventilation, as well as a failure to consider unique characteristics of the patients’ history and physical status that place them at higher risk for respiratory depression from opioid analgesics.
Standardized protocols for PCA or neuraxial opioids may promote a “one size fits all” approach to pain management without sufficient consideration of individual patient characteristics and medical conditions. Continuous pulse oximetry is not being routinely employed. More commonly, respiratory monitoring relies on nurses’ periodic observation and documentation of breathing or respiratory rate. Even when continuous pulse oximetry is utilized, supplemental oxygen may be administered, sometimes without confirming its necessity or appreciating its potential to mask progressive hypoventilation.
It is critically important to emphasize the need to individualize postoperative pain management (opioid dose and infusion rate are not the same for every patient) and to insist that continuous monitoring of oxygenation (pulse oximetry) be the routine and not the exception. The use of supplemental oxygen must be justified. Finally, during PCA or neuraxial opioid therapy, intermittent subjective assessments of ventilation or level of consciousness are unreliable predictors of future respiratory depression, even over short time frames (10-15 minutes).
We recommend consideration of the use of technology to continuously monitor ventilation in all patients receiving postoperative PCA or neuraxial opioid pain management. Where appropriate, this should be a routine component of postoperative care in patients known to be at high risk for opioid-induced respiratory depression (existing depressed level of consciousness or respiratory impairment, sleep apnea, or the very sick or elderly). Even if ventilation assessments are performed intermittently during routine nursing observations, the use of respiratory monitoring technology (capnometry) would improve the detection of progressive or unrecognized hypoventilation.
In summary, we believe that every patient receiving postoperative opioid analgesics should be managed based on the following clinical considerations:
Unrecognized postoperative opioid-induced respiratory depression can be reliably detected only if an understanding of the pathophysiology of the sequence of events and available monitoring technology are considered in all patients.